In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

The efficacy of nicorandil for patients with ischemic chronic heart failure

Session Poster Session 2

Speaker Florina Batar

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure: Pharmacotherapy
  • Session type : Poster Session

Authors : FG Batar (Sibiu,RO), S Batar (Sibiu,RO), R Mitea (Sibiu,RO), I Bitea (Sibiu,RO), G Eminovici (Sibiu,RO), M Teodoru (Sibiu,RO), I Manitiu (Sibiu,RO)

Authors:
FG Batar1 , S Batar2 , R Mitea2 , I Bitea3 , G Eminovici2 , M Teodoru2 , I Manitiu2 , 1County Hospital, Cardiology - Sibiu - Romania , 2Lucian Blaga University - Sibiu - Romania , 3County Hospital, CVAIC Centre - Sibiu - Romania ,

Citation:

BACKGRAUND Nicorandil, combination of nitrate component and sarcolemmal adenosine triphosphate-sensitive potassium channel opener, is a potent vasodilator of coronary and peripheral vessels and has been used as an antianginal agent, but its effect in heart failure (HF) patients has not been fully established. Therefore, we examined impacts of nicorandil in ischemic HF patients in a small cohort.

PURPOSE  To assess the efficacy of therapy with nicorandil in hospitalized with ischemic chronic heart failure.

METODS 12 HF patients with ischemic etiology were prospectively registered and divided into 2 groups based on oral administration of nicorandil during hospitalization : nicorandil group (n = 6) and non-nicorandil group (n=6). Patients were randomly assigned to be treated with or without oral nicorandil. BNP levels were measured at admission and at 5th day. Echocardiography was performed and the patients undergo cardiopulmonary exercise test.

RESULTS 66,6% of the patients were men, mean age was 67 years and mean length of inpatient stay was 7.8 days.  We found a positive correlation between initial BNP and the number of hospitalized days in nicorandil group (r=0.64) and a negative correlation between initial BNP and the number of hospitalized days in non-nicorandil group (r=-0.73). The difference between levels of BNP after 5 days of treatment and initial BNP in the two groups is statistically significant (p=0.038).  Ventilatory efficiency (VE/Vco2) is significantly different between the two groups (p=0.022).

Conclusion: The patients in the nicorandil group had higher decrease of BNP levels without shortening the length of hospitalization. Further studies with larger cohorts are needed.

nicorandil group non-nicorandil group p
age 63.8±4.19 69.7±5.6 0.26
male 66.6% 66.6%
LVEF (%) 39.33 39.83 0.95
E/e 6.62±2.2 8.13±0.7 0.17
MAPSE 11.2±2.5 12.8±5.1 0.71
ΔBNP 221 14 0.038
LVEF left ventricular ejection fraction, BNP B-type natriuretic peptide, MAPSE mitral annular plane systolic excursion

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are